Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically designed for research applications focused on metabolic health and body composition. This 44-amino acid peptide is primarily investigated for its role in stimulating the secretion of growth hormone (GH), which subsequently influences insulin-like growth factor 1 (IGF-1) levels. Researchers utilize tesamorelin to explore its effects on visceral fat reduction, particularly in models of aging and HIV-associated lipodystrophy.

Studies have demonstrated that tesamorelin effectively targets abdominal adipose tissue, promoting increased lipolytic activity and activation of the GH/IGF-1 axis. Clinical research indicates significant reductions in visceral fat mass and waist circumference, making it a valuable compound for investigating obesity-related metabolic disorders. Additionally, tesamorelin has shown potential in improving lipid profiles, enhancing insulin sensitivity, and regulating triglyceride levels, which are critical factors in the study of metabolic syndrome and dyslipidemia.

Furthermore, tesamorelin may contribute to the preservation of lean body mass and support cognitive function through GH-mediated pathways. This aspect is particularly relevant in research related to age-related sarcopenia and the management of hepatic fat accumulation. Overall, tesamorelin serves as a significant tool for researchers aiming to understand the complex interactions between growth hormone, metabolism, and body composition.

For research and laboratory use only. Not for human consumption.